Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GCKR | Q14397 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5796164 | 1.00 | MAPT (0.47) | MAPTTP53SMN1; SMN2PTGDRCHRM2 | |
| SCHEMBL5746231 | 0.89 | CHRM2 (0.49) | MAPTTP53SMN1; SMN2PTGDRCHRM2 | |
| SCHEMBL6351657 | 0.89 | CHRM2 (0.49) | MAPTTP53SMN1; SMN2PTGDRCHRM2 | |
| SCHEMBL5776562 | 0.86 | PTGDR (0.48) | MAPTSMN1; SMN2PTGDREPHX1EPHX2 | |
| SCHEMBL5480678 | 0.84 | PPARD (0.52) | CHRM2PTGDR2EPHX1EPHX2 | |
| SCHEMBL6353284 | 0.83 | HSD11B1 (0.51) | PTGDRCHRM2GCKR | |
| SCHEMBL6353286 | 0.83 | HSD11B1 (0.51) | PTGDRCHRM2GCKR | |
| SCHEMBL13805002 | 0.81 | ALDH1A1 (0.48) | SMN1; SMN2POLBLMNA | |
| SCHEMBL5775860 | 0.81 | MAPT (0.61) | MAPTTP53POLBNAMPTRECQL | |
| SCHEMBL13805215 | 0.81 | GAA (0.54) | EPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | KALYPSYS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | PPARA, PPARG, PPARD | MAPT 4579/4885TP53 2986/4885SMN1; SMN2 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.